Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Baxter
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Litigation Details for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-12-11
Court District Court, D. Delaware Date Terminated 2010-07-13
Cause 35:271 Patent Infringement Assigned To Joseph James Farnan Jr.
Jury Demand None Referred To
Parties ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA UK LIMITED; IPR PHARMACEUTICALS INC.; SANDOZ INC.; SHIONOGI SEIYAKU KABUSHIKI KAISHA
Patents 6,316,460; 6,589,959; 6,858,618
Attorneys Charles E. Lipsey; Colleen Tracy; Daniel V. Folt; Darren Scott Mogil; Edward V. Di Lello; Ford F. Farabow; George H. Seitz , III; Henry J. Renk; John D. Livingstone; Kenneth M. Frankel; Martin B. Pavane; Mary K. Ferguson; Mary W. Bourke; Richard William Riley; York M. Faulkner
Firms Duane Morris, LLP; Womble Carlyle Sandridge & Rice, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in AstraZeneca Pharmaceuticals LP v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2008-01-31 12 Answer to Complaint .S. Patent No. 6,858,618 (“the ‘61 8 patent”) and U.S. Patent No. 6,589,959 (“the ‘959 patent”) are invalid…belief that the ‘314 patent, the ‘460 patent, the ‘618 patent, and the ‘959 patent were invalid, unenforceable… to enforce the ‘314 patent, the ‘460 patent, the ‘618 patent and the ‘959 patent First Counterclaim-… that U.S. Patent No. RE37,314 (“the 314 patent”) was reissued by the United States Patent and Trademark… States Patent and Trademark foice (“PTO”) with respect to the ‘3 14 patent and/or U.S. Patent No. 5,260,440 External link to document
2008-03-28 23 Redacted Document 6,858,618 (‘;the ‘618 patent”), and 6,589,959 (“the ‘959 patent”). The ‘460 and ‘618 patents are listed in “…noninfringement of three patents not asserted by AstraZeneca-U.S. Patent Nos. 6,316,460 (“the ‘460 patent”), 6,858,618…Related to the ‘959 Patent Cannot Lie Unlike the ‘460 and ‘618 patents, the ‘959 patent is not listed in… for infringement of U.S. Reissue Patent RE37,314 (“the ‘3 14 patent”) under 35 U.S.C. § 271(e)(2)(A) …challenge the ‘3 14 patent In an effort to resolve the multiple challenges to its patent rights, AstraZeneca External link to document
2008-05-21 39 Stipulation of Dismissal FOR RELIEF RELATING TO U.S. PATENT NOS. 6,316,460; 6,858,618; AND 6,589,959 by AstraZeneca Pharmaceuticals…RELATING TO U.S. PATENT NOS. 6,316,460; 6,858,618; AND 6,589,959 IT IS HEREBY STIPULATED…for Relief relating to U.S. Patent Nos. 6,316,460; 6,858,618; and 6,589,959 in Answer, Affirmative Defenses…2007 13 July 2010 1:07-cv-00807 830 Patent None District Court, D. Delaware External link to document
2008-06-10 43 Order for Relief Relating to U.S. Patent Nos. 6,316,460; 6,858,618; and 6,589,959, filed by IPR Pharmaceuticals… REL[EF RELATING TO U.S. PATENT NOS. 6,316,460; 6,858,618,' AND 6,589,959 IT IS HEREBY STIPULATED…for Relief relating to U.S. PatentN os. 6,316,460; 6,858,618; and 6,589,959 in Answer, Affirmative Defenses…2007 13 July 2010 1:07-cv-00807 830 Patent None District Court, D. Delaware External link to document
2008-11-24 58 8The Florida action relates to U.S. Patent No. 6,316,460, for which AstraZeneca is the owner and…States Patent and Trademark Office took to grant a patent, a manufacturer's patent term was…section) alleging patent infringement. AstraZeneca holds all substantial rights in U.S. Patent No. RE37,314…testing (a use) of a patented product prior to the expiration of the patent an act of infringement… Fourth, a patent holder in receipt of a Paragraph IV Certification which files a patent infringement External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Merck
Medtronic
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.